Silodosin
FDA-approved product (capsule, oral), marketed as Rapaflo, Silodosin.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Benign prostatic hyperplasia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Alpha-adrenoreceptor antagonists
- FDA pharmacologic class
- alpha-Adrenergic Blocker FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Silodosin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Galantamine HydrobromideExisting use: Alzheimer disease, Dementia89.6% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more69.3% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives68.0% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- ElvitegravirExisting use: HIV infection, HIV-1 infection, Viral disease60.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more57.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm56.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more56.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome56.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more54.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia52.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis52.2% AI-predicted activityagainst K. pneumoniae28 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Comparison of Silodosin and Tamsulosin for Medical Expulsive Therapy in Patients With Ureteral Stones
NCT06999135 · start 2023-10-01
Registered record
- Registry ID
- NCT06999135
- Conditions
- Tamsulosin; Silodosin; Medical Expulsive Therapy
- Interventions
- Silodosin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2023-10-01
- Completion
- 2024-08-15
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTamsulosin; Silodosin; Medical Expulsive TherapyInterventionSilodosinPhaseNot applicableRegistry statusCompletedThe Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention
NCT06319469 · start 2023-02-01
Registered record
- Registry ID
- NCT06319469
- Conditions
- Prostatic Hyperplasia
- Interventions
- silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet; silodosin 8 mg capsule
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2023-02-01
- Completion
- 2024-01-30
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstatic HyperplasiaInterventionsilodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet; silodosin 8 mg capsulePhasePhase 2Registry statusCompletedEffect of Preoperative Silodosin on Feasibility of Ureteral Access Sheath Insertion
NCT05833386 · start 2022-10-01
Registered record
- Registry ID
- NCT05833386
- Conditions
- Renal Stone
- Interventions
- Ureteral access sheath placement during flexible ureteroscope for renal stones
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2022-10-01
- Completion
- 2026-08-01
- Enrolment
- 2,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenal StoneInterventionUreteral access sheath placement during flexible ureteroscope for renal stonesPhaseNot applicableRegistry statusUnknownThe Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
NCT05551221 · start 2022-09-21
Registered record
- Registry ID
- NCT05551221
- Conditions
- Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
- Interventions
- Silodosin Capsules; Tamsulosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2022-09-21
- Completion
- 2024-09-10
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic Hyperplasia With Lower Urinary Tract SymptomsInterventionSilodosin Capsules; TamsulosinPhasePhase 4Registry statusCompletedThe Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH
NCT07134907 · start 2022-07-18
Registered record
- Registry ID
- NCT07134907
- Conditions
- BPH (Benign Prostatic Hyperplasia)
- Interventions
- Silodosin; Tamsolusin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2022-07-18
- Completion
- 2024-07-09
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBPH (Benign Prostatic Hyperplasia)InterventionSilodosin; TamsolusinPhasePhase 4Registry statusCompletedSilodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones
NCT05789732 · start 2022-03-30
Registered record
- Registry ID
- NCT05789732
- Conditions
- Lower Ureteric Stones; Medical Expulsive Therapy; Tadalafil; Silodosin
- Interventions
- Placebo; Silodosin; Tadalafil; Silodosin and Tadalafil
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-03-30
- Completion
- 2022-08-30
- Enrolment
- 168
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLower Ureteric Stones; Medical Expulsive Therapy; Tadalafil; SilodosinInterventionPlacebo; Silodosin; Tadalafil; Silodosin and TadalafilPhaseNot applicableRegistry statusCompletedDouble J Stenting and Sildosin After URSL for Lower Ureteric Stones
NCT05823662 · start 2022-03-02
Registered record
- Registry ID
- NCT05823662
- Conditions
- Lower Ureteric Stones; Ureteroscopic Lithotripsy; DJ Stenting
- Interventions
- DJ stent; Silodosin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-03-02
- Completion
- 2023-03-02
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLower Ureteric Stones; Ureteroscopic Lithotripsy; DJ StentingInterventionDJ stent; SilodosinPhaseNot applicableRegistry statusCompletedEfficacy and Safety of Silodosin in the Treatment of Lower Urinary Tract Symptoms in Taiwanese Population.
NCT06332235 · start 2022-02-18
Registered record
- Registry ID
- NCT06332235
- Conditions
- Human Trichinellosis
- Interventions
- Silodosin 8 mg
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2022-02-18
- Completion
- 2024-12-31
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHuman TrichinellosisInterventionSilodosin 8 mgPhaseNot recordedRegistry statusUnknownIntermittent Catheterization Versus Trial Without Catheter
NCT05094947 · start 2021-08-03
Registered record
- Registry ID
- NCT05094947
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- intermittent catheterization; trial without catheter; alpha-blockers
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2021-08-03
- Completion
- 2022-05
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionintermittent catheterization; trial without catheter; alpha-blockersPhaseNot applicableRegistry statusUnknownEffect of Preoperative Alpha-blockers on Successful Insertion Ureteral Access Sheath and Reduce Ureteral Injury in Non-prestented Patients During RIRS. Assessment of Factors for Successful Ureteral Access Sheath Insertion.
NCT07202923 · start 2021-07-09
Registered record
- Registry ID
- NCT07202923
- Conditions
- Urolithiasis; Ureteral Injury; Ureteral Access Sheath; Retrograde Intrarenal Surgery
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2021-07-09
- Completion
- 2024-06-02
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrolithiasis; Ureteral Injury; Ureteral Access Sheath; Retrograde Intrarenal SurgeryInterventionNot recordedPhaseNot recordedRegistry statusCompletedEvaluation of Silodosin and Pelvic Floor Muscle Training in Men With Benign Prostatic Hyperplasia and Overactive Bladder
NCT04681625 · start 2021-01-11
Registered record
- Registry ID
- NCT04681625
- Conditions
- Benign Prostatic Hyperplasia (BPH); Overactive Bladder
- Interventions
- Pelvic floor muscle training (PFMT) with suppressive urgency technique
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2021-01-11
- Completion
- 2022-09-30
- Enrolment
- 172
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic Hyperplasia (BPH); Overactive BladderInterventionPelvic floor muscle training (PFMT) with suppressive urgency techniquePhaseNot applicableRegistry statusCompletedEfficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)
NCT04107896 · start 2017-08-31
Registered record
- Registry ID
- NCT04107896
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Silodosin; Tamsulosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2017-08-31
- Completion
- 2018-08-31
- Enrolment
- 141
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionSilodosin; TamsulosinPhasePhase 4Registry statusCompletedComparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
NCT02220829 · start 2016-06
Registered record
- Registry ID
- NCT02220829
- Conditions
- Urinary Problems; Prostate Cancer
- Interventions
- Preventive administration of Rapaflo; Standard Care
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-06
- Completion
- 2023-08
- Enrolment
- 148
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrinary Problems; Prostate CancerInterventionPreventive administration of Rapaflo; Standard CarePhasePhase 3Registry statusCompletedA Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
NCT02431754 · start 2015-04
Registered record
- Registry ID
- NCT02431754
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Tadalafil; Placebo; Alpha1 Blocker
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-04
- Completion
- 2016-02
- Enrolment
- 171
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionTadalafil; Placebo; Alpha1 BlockerPhasePhase 4Registry statusCompletedEffectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.
NCT02090439 · start 2014-07
Registered record
- Registry ID
- NCT02090439
- Conditions
- Kidney Stone; Expulsive Medical Therapy
- Interventions
- Silodosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2014-07
- Completion
- 2015-12
- Enrolment
- 8
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney Stone; Expulsive Medical TherapyInterventionSilodosinPhasePhase 3Registry statusTerminated